kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human PDGF-BB, 50µg  

ActiveMax® Recombinant Human PDGF-BB, 50µg

Recombinant Human PDGF-BB (ActiveMax® Human PDGF-BB) Ser 82 - Thr 190 was produced in human 293 cells (HEK293), ActiveMaxCytokine


More details


Availability: within 7 days

420,00 €

Background: PDGFs are mitogenic during early developmental stages, driving the proliferation of undifferentiated mesenchyme and some progenitor populations. During later maturation stages, PDGF signalling has been implicated in tissue remodelling and cellular differentiation, and in inductive events involved in patterning and morphogenesis. In addition to driving mesenchymal proliferation, PDGFs have been shown to direct the migration, differentiation and function of a variety of specialised mesenchymal and migratory cell types, both during development and in the adult animal. Other growth factors in this family include vascular endothelial growth factors B and C (VEGF-B, VEGF-C)which are active in angiogenesis and endothelial cell growth, and placenta growth factor (PlGF) which is also active in angiogenesis. PDGF plays a role in embryonic development, cell proliferation, cell migration, and angiogenesis. PDGF is a required element in cellular division for fibroblast, a type of connective tissue cell. PDGF is also known to maintain proliferation of oligodendrocyte progenitor cells. Platelet-derived growth factor subunit B is also known as PDGFB, FLJ12858, PDGF2, SIS, SSV, c-sis, is a member of the platelet-derived growth factor family. PDGFB can exist either as a homodimer (PDGF-BB) or as a heterodimer with the platelet-derived growth factor alpha polypeptide (PDGF-AB), where the dimers are connected by disulfide bonds. Mutations in this gene are associated with meningioma.

ActiveMax® Recombinant Human PDGF-BB (ActiveMax® Human PDGF-BB) Ser 82 - Thr 190 (Accession # AAH29822) was produced in human 293 cells (HEK293)

Molecular Characterization
rhPDGF-BB is a disulfide-linked homodimeric polypeptide chain containing 2×109 amino acids, and has a calculated MW of 25 kDa. The reducing (R) protein migrates as a 15 kDa polypeptide and the non-reducing (NR) disulfide-linked homodimer migrates as a 28.

Less than 1.0 EU per μg of the ActiveMax® Human PDGF-BB by the LAL method.

>90% as determined by  reducing (R) and non-reducing (NR) SDS-PAGE. 

Lyophilized from 0.22 μm filtered solution in Acetonitrile and TFA. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Measured by its binding ability in a functional ELISA. Immobilized ActiveMax® Human PDGF-BB (Catalog # PDB-H4219) at 5 µg/mL(100 µl/well) can bind Human PDGF R beta, Fc Tag (Catalog # PDB-H5252) with a linear range of 0.02-0.6 µg/mL (QC tested). The bio-activity was determined by dose-dependent stimulation of the proliferation of mouse 3T3 cells. The ED50 was 0.5-20 ng/mL(Routinely tested).


(1) Hoch RV, Soriano P. 2003, Development 130 (20): 4769–4784.
(2) Olofsson B, et al. 1996, Proc Natl Acad Sci U S A.,93(6):2576-81.
(3) Joukov V, et al. 1996, EMBO J. 15 (2): 290–298.
(4) Lei KJ, et al. 1993, Oncogene 8 (4): 925–931.
(5) Ratner L, et al. 1985, Nucleic Acids Res 13 (14): 5007–18.